Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.

Similar presentations


Presentation on theme: "Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation."— Presentation transcript:

1 Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708. doi:10.7326/0003-4819-159-10-201311190-00718 Medications for risk reduction of primary breast cancer in women: clinical summary of U.S. Preventive Services Task Force recommendation. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2 Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708. doi:10.7326/0003-4819-159-10-201311190-00718 Benefit–risk indices for tamoxifen and raloxifene chemoprevention in white non-Hispanic women with a uterus, by age group and level of 5-y projected risk for invasive breast cancer. Reproduced from Freedman and colleagues (8) with permission from the American Society of Clinical Oncology. This figure remains the property of the American Society of Clinical Oncology and is not part of the public domain. BCPT = Breast Cancer Prevention Trial; IBC = invasive breast cancer; RR = relative risk; STAR = Study of Tamoxifen and Raloxifene; WHI = Women's Health Initiative. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3 Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708. doi:10.7326/0003-4819-159-10-201311190-00718 Benefit–risk indices for tamoxifen and raloxifene chemoprevention in black women with a uterus, by age group and level of 5-y projected risk for invasive breast cancer. Reproduced from Freedman and colleagues (8) with permission from the American Society of Clinical Oncology. This figure remains the property of the American Society of Clinical Oncology and is not part of the public domain. BCPT = Breast Cancer Prevention Trial; IBC = invasive breast cancer; RR = relative risk; STAR = Study of Tamoxifen and Raloxifene; WHI = Women's Health Initiative. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4 Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708. doi:10.7326/0003-4819-159-10-201311190-00718 Benefit–risk indices for tamoxifen and raloxifene chemoprevention in white non-Hispanic women without a uterus, by age group and level of 5-y projected risk for invasive breast cancer. Reproduced from Freedman and colleagues (8) with permission from the American Society of Clinical Oncology. This figure remains the property of the American Society of Clinical Oncology and is not part of the public domain. BCPT = Breast Cancer Prevention Trial; IBC = invasive breast cancer; RR = relative risk; STAR = Study of Tamoxifen and Raloxifene; WHI = Women's Health Initiative. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

5 Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708. doi:10.7326/0003-4819-159-10-201311190-00718 Benefit–risk indices for tamoxifen and raloxifene chemoprevention in black women without a uterus, by age group and level of 5-y projected risk for invasive breast cancer. Reproduced from Freedman and colleagues (8) with permission from the American Society of Clinical Oncology. This figure remains the property of the American Society of Clinical Oncology and is not part of the public domain. BCPT = Breast Cancer Prevention Trial; IBC = invasive breast cancer; RR = relative risk; STAR = Study of Tamoxifen and Raloxifene; WHI = Women's Health Initiative. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians


Download ppt "Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation."

Similar presentations


Ads by Google